AllianceBernstein’s Tango Therapeutics TNGX Stock Holding History

AllianceBernstein’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.35M	Buy	160,010 +42,390	+36%	+$1.05M	﹤0.01%	1771
2026 Q1	$1.04M	Buy	117,620 +11,130	+10%	+$155K	﹤0.01%	2327
2025 Q4	$944K	Buy	106,490 +4,220	+4%	+$36.4K	﹤0.01%	2373
2025 Q3	$859K	Sell	102,270 -3,740	-4%	-$25.3K	﹤0.01%	2414
2025 Q2	$543K	Buy	106,010 +41,070	+63%	+$102K	﹤0.01%	2593
2025 Q1	$89K	Hold	64,940	–	–	﹤0.01%	3080
2024 Q4	$201K	Hold	64,940	–	–	﹤0.01%	3023
2024 Q3	$500K	Hold	64,940	–	–	﹤0.01%	2663
2024 Q2	$557K	Buy	64,940 +16,980	+35%	+$131K	﹤0.01%	2617
2024 Q1	$381K	Buy	47,960 +11,320	+31%	+$121K	﹤0.01%	2710
2023 Q4	$363K	Buy	36,640 +8,480	+30%	+$73.6K	﹤0.01%	2763
2023 Q3	$317K	Hold	28,160	–	–	﹤0.01%	2784
2023 Q2	$93.5K	Buy	28,160 +12,360	+78%	+$44.5K	﹤0.01%	3086
2023 Q1	$62.4K	Buy	15,800 +2,800	+22%	+$16.3K	﹤0.01%	3078
2022 Q4	$94.3K	Buy	+13,000	New	+$91.4K	﹤0.01%	3118

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

AllianceBernstein's TNGX Position: Q2 2026 in Review

AllianceBernstein increased its Tango Therapeutics (TNGX) stake by 36% in Q2 2026, buying an estimated $1.05M and bringing the position to 160,010 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

AllianceBernstein first reported a position in TNGX in Q4 2022 and has held it in 15 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

AllianceBernstein held 160,010 shares of Tango Therapeutics worth $3.35M as of Q2 2026.
AllianceBernstein bought 42,390 Tango Therapeutics shares in Q2 2026, an estimated $1.05M.
Tango Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1771 holding.
AllianceBernstein first reported a position in Tango Therapeutics in Q4 2022 and has held it in 15 quarters since.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.